Prescription Patterns of Antidiabetic Treatment in the Elderly. Results from Southern Italy

Abstract

The treatment of diabetes in the elderly is a major challenge both in terms of clinical management and of public health. Evidence about prescribing patterns in the elderly diabetic population is limited. The aim was to describe trends in antidiabetic drug (AD) utilization patterns in the elderly in Southern Italy with a focus on drugs for cardiovascular prevention and pharmaceutical costs. The data used for this study were obtained from pharmacy records of Caserta Local Health Authority, a province in Southern Italy with 1 million of inhabitants, comprising urban and rural areas. Subjects above 65 years who received at least one dispensing of antidiabetic between January 2010 and December 2014 were selected. Prevalence and incidence rates (%) of AD use were calculated for each calendar year and stratified by class therapy and age group. Sub-analyses by cardiovascular co-medication therapy and pharmaceutical cost analysis were performed. The prevalence rate decreases from 22.0% in 2010 to 17.5% in 2014 (p<0.001). Proportion of subjects treated with monotherapy increases over the study period (33.9% in 2010; 38.6% in 2014; p<0.001). In particular, increases the proportion of users of metformin (18.2% in 2010; 23.7% in 2014; p<0.001), while the proportion of users of sulfonylureas dropped (11.0% in 2010; 7.2% in 2014; p< 0.001). About 90% of elderly diabetic patients are treated with drugs for cardiovascular prevention. The per/patient/yearly drug costs were 2,349 €: 28.5% for AD therapy and 71.5% for other treatments. Trend in drug utilization patterns showed a tendency towards treatment recommendations in older adults.

Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry

“…A recent study ( 39 ) focusing on antidiabetic treatment among elderly Italian people >65 years of age reported similar percentages of insulin-only treatment (15.7%) and OAD-only treatment (38.6%) compared with our study. Compared with the Italian study (9.3%), the use of combined insulin/OAD therapy reported by our study (17.9%) is relatively high.…”

Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy

“…The Campania Region Database (CaReDB) includes information on patient demographics, the electronic records of outpatient pharmacy dispensing and hospital discharges for ~6 million residents of a well-defined population in Italy (~10% of the population of Italy). CaReDB is complete and includes validated data in previous drug utilization studies [9][10][11][12][13][14][15][16][17]. The characteristics of CaReDB are described in S1 Table. From the beginning of the Covid-19 epidemic, a surveillance system was implemented to collect all cases identified by reverse transcription-polymerase chain reaction (RT-PCR) testing for SARS-CoV-2.…”

New professional roles and patient satisfaction: Evidence from a European survey along three clinical pathways

“…reduction of waiting lists, decrease in the re-admission rates). This is even more relevant for chronic conditions involving a growing old population [21]. Nonetheless it should be remembered that satisfaction is…”

“…It also provides a good incentive for countries like Italy where the task substitution from medical staff to other professionals (e.g. nurses) is perceived as a necessity due to budget constraints and medical staff shortages, but there are still cultural barriers that slow down this process at least in some regions (with the Northern Italy being more keen on involving new health professional roles in some disease pathways [20][21][22]).…”